In CML, the BCR-ABL fusion protein short-circuits CSF2 signaling via downstream activation of STAT5 (Carlesso et al., 1996; Hantschel et al., 2012; Minami et al., 2008). The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.